Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
11/09/2023 13:39
Sept 11 (Reuters) - Paratek Pharmaceuticals Inc
PRTK.O :
* PARATEK PHARMACEUTICALS-HAS RECEIVED SIX DEMANDS MADE
PURSUANT
TO SECTION 220 OF DELAWARE GENERAL CORPORATION LAW SEEKING
CERTAIN BOOKS,RECORDS OF CO
* PARATEK PHARMACEUTICALS - GOT DEMAND LETTERS FROM 11
STOCKHOLDERS ALLEGING "MISLEADING", INCOMPLETE STATEMENTS IN
PROXY STATEMENT FILED ON JUNE 30
* PARATEK PHARMACEUTICALS INC - BELIEVES THAT CLAIMS
ASSERTED IN
DEMANDS ARE WITHOUT MERIT
* PARATEK PHARMACEUTICALS INC - DENIES THAT ANY FURTHER
DISCLOSURE
BEYOND THAT ALREADY CONTAINED IN PROXY STATEMENT IS REQUIRED
* PARATEK PHARMACEUTICALS - WITHOUT ADMITTING ANY LIABILITY
OR
WRONGDOING, CO IS MAKING SUPPLEMENTAL DISCLOSURES TO PROXY
STATEMENT
Further company coverage: PRTK.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million